Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Pravachol investigation

Executive Summary

Bristol-Myers Squibb receives civil investigative demand from Missouri Attorney General relating to Pravachol DTC advertising from 2001-2003, 1Bristol's 10-K filing says. A separate, class action 2complaint filed in Kansas City, Mo. state court alleges the ads misled consumers "into purchasing Pravachol under the mistaken belief that it would help prevent strokes in people with high cholesterol even if they did not have any history of heart disease." In an August 2003 warning letter, FDA said the ads falsely implied that pravastatin is approved for prevention of stroke in patients without coronary heart disease (3"The Pink Sheet" Aug. 11, 2003, p. 4). Bristol issued a corrective ad in February. [Editor's note: For more coverage, log on to 4"The Pink Sheet" DAILY. Visit our website, www.ThePinkSheetDAILY.com to sign up for a free trial.]...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel